Design Therapeutics (DSGN) earnings

Healthcare · Biotechnology · Market cap $669M

In the quarter ended June 2026, Design Therapeutics had revenue of $0, and diluted EPS of -0.32.

On August 3, 2026 it reported EPS of -0.32 against an estimate of -0.36 (beat).

The next report is expected on Wednesday, November 4, 2026, with EPS expected around -0.38.

Report dates

ReportDateTimeEPS estimateEPS reported
NextWed Nov 4, 2026 — -0.38 —
LastMon Aug 3, 2026 — -0.36 -0.32

Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.

Quarterly results

The last 12 quarters from Design Therapeutics's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.

Quarter endedRevenueGrowthEPS (diluted)GrowthOp. marginFiled
Jun 30, 2026$0 — -0.32 — — 2026-08-03
Mar 31, 2026$0 — -0.29 — — 2026-04-28
Dec 31, 2025$0 — — — — 2026-03-09
Sep 30, 2025$0 — -0.30 — — 2025-11-05
Jun 30, 2025$0 — -0.34 — — 2025-08-07
Mar 31, 2025$0 — -0.31 — — 2025-05-07
Dec 31, 2024— — — — — 2025-03-10
Sep 30, 2024— — -0.23 — — 2024-11-07
Jun 30, 2024— — -0.21 — — 2024-08-05
Mar 31, 2024— — -0.20 — — 2024-05-08
Dec 31, 2023— — — — — 2024-03-19
Sep 30, 2023— — -0.28 — — 2023-11-13
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DSGN.
Open DSGN in Investingly

Questions

When does Design Therapeutics report earnings?

Design Therapeutics's next earnings report is expected on November 4, 2026.

How did Design Therapeutics do last quarter?

In the quarter ended June 2026, Design Therapeutics had revenue of $0, and diluted EPS of -0.32.

From Design Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.